Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Bullish option flow detected in Novavax (NVAX) with 33,054 calls trading, 2x expected, and implied vol increasing over 1 point to 67.01%. Aug-25 ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

(Reuters) -Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone ...

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy children under 5 years old, the company confirmed Wednesday.  The move ...

Novavax says its Covid-19 vaccine is 90 percent effective overall and 100 percent effective against severe disease. If authorized by the FDA, it would be the country's fourth vaccine.